Mustang Bio, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies based on the ground breaking Chimeric Antigen Receptor (CAR) research of Dr. Stephen Forman and Dr. Christine Brown of City of Hope, an NCI-designated Comprehensive Cancer Center. Mustang was formed to help bring this pioneering CAR research to as many patients as possible. Mustang, through a research agreement with COH, will develop CARs across multiple cancers, including for AML and Brain Cancer. Both of the lead programs are in phase I clinical trials.
Mustang believes that harnessing the body’s own immune system to treat cancer is the next generation of cancer care that may prove curative across tumor types that have proved resilient to standard pharmacological and biological treatments. CAR-T uses the patient’s own T-cells to engage and destroy specific tumors. The process involves selecting specific T-cell subtypes, genetically engineering them to express chimeric antigen T-cell receptors and placing them back in the patient where they recognize and destroy cancer cells.
Mustang’s exclusive license and sponsored research agreement at the COH encompasses specific chimeric T-cell constructions and enabling process technologies including linker technology improvements. This agreement covers the discovery, manufacturing and clinical development of novel Chimeric Antigen Receptor engineered T-cells (CAR-T) along with specified rights to any and all inventions.
Two of the CAR-T’s from our collaboration with the COH are already in phase I clinical development. The first is a proprietary engineered Chimeric Antigen Receptor T-cells targeting interleukin 13 Receptor α2 which is overexpressed on the surface of glioblastoma (GBM) cells.
The second is a proprietary CAR-T targeting of CD123, which is overexpressed on the surface of Acute Myeloid Leukemia (AML) cells.
Mustang also has a sponsored preclinical research agreement in place with COH to develop additional CAR-T cell products.